Questran can be mixed with water, juice, or a non-carbonated beverage and taken with or without food. Taking it with a full glass of liquid helps the powder disperse and reduces the likelihood of gastrointestinal discomfort.
Each sachet contains a white, fine powder. Inactive components typically include sodium, calcium, and magnesium salts that aid in the binding of bile acids. The exact excipient list is printed on the product label.
Most patients observe a measurable decline in LDL-cholesterol within 1-2 weeks, with the greatest reduction occurring after about 4-6 weeks of consistent dosing.
Questran is a prescription medicine in the UK. When traveling, keep it in its original packaging with the prescription label and carry a copy of the prescribing doctor’s note. This helps avoid confusion at security checkpoints.
Cholestyramine does not contain substances that trigger standard drug-screening assays. However, it may interfere with the absorption of other medications that could be detected, so disclose all medicines to testing authorities.
Increase fluid intake, add dietary fibre, and consider a mild osmotic laxative after consulting a pharmacist or doctor. If constipation becomes obstructive or is accompanied by abdominal pain, seek medical attention promptly.
Because cholestyramine can reduce the absorption of fat-soluble vitamins (A, D, E, K), clinicians often recommend a daily multivitamin or specific vitamin supplements, especially for patients on high-dose regimens.
In cases of obstructive jaundice or severe cholestasis, Questran may worsen pruritus and is generally avoided. Patients with other forms of chronic liver disease may use it under close supervision.
All cholestyramine products contain the same active polymer and work by the same mechanism. Differences may lie in packaging (sachet versus powder) or the presence of specific flavourings, but clinical efficacy is comparable.
Keep the sachets in a cool, dry place away from direct sunlight. If the ambient temperature exceeds 30 °C, store the product in a climate-controlled environment or a refrigerator (do not freeze). Ensure the container remains tightly sealed to prevent moisture ingress.
Questran contains cholestyramine as its active component. It is a bile-acid sequestrant formulated as a 4 g powdered sachet for oral use. In the United Kingdom Questran is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The product is used primarily to lower elevated blood cholesterol and to manage certain types of pruritus and diarrhoea caused by bile-acid malabsorption.
Cholestyramine is a high-molecular-weight polymer that binds bile acids in the gastrointestinal tract. By forming an insoluble complex, it prevents the entero-hepatic recycling of bile acids. The loss of bile acids in the stool forces the liver to synthesise new bile acids from circulating cholesterol, thereby reducing low-density lipoprotein (LDL) cholesterol levels. This mechanism also reduces the amount of bile acids that can irritate the skin or stimulate watery bowel movements in conditions such as cholestasis and bile-acid malabsorption.
Key pharmacologic points
Because cholestyramine is not absorbed systemically, it has minimal direct systemic toxicity, but its binding capacity can interfere with the absorption of other oral agents and fat-soluble vitamins.
These indications are approved by the MHRA for use in the United Kingdom. In clinical practice, physicians may also prescribe Questran for related disorders where bile-acid sequestration is beneficial, provided that the patient is monitored appropriately.
These applications are not formally approved by the MHRA. Off-label use requires medical supervision and an individualized risk-benefit assessment.
Cholestyramine can decrease the absorption of several medications. To minimise interaction risk, separate the administration of Questran and the other oral agent by at least 1 hour (Questran before, the other drug after).
This article provides educational information about Questran and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
